Cimetidine/Cyclophosphamide/Diclofenac/Salazosulfapyridine

西咪替丁/环磷酰胺/双氯芬酸/柳氮磺吡啶

Report date: 2023/05/16 16:59:27

Base Information

Drug NameCimetidine/Cyclophosphamide/Diclofenac/Salazosulfapyridine

Drug Alias Namediclofenac + sulfasalazine+cimetidine + cyclophosphamide柳氮磺吡啶/西咪替丁/环磷酰胺/双氯芬酸环磷酰胺/西咪替丁/双氯芬酸/柳氮磺吡啶Cyclophosphamide/Cimetidine/Diclofenac/Salazosulfapyridine环磷酰胺/双氯芬酸/西咪替丁/柳氮磺吡啶 +[11]

ClassificationSmall molecules

Mechanisms of ActionCyclooxygenases inhibitorsHistamine H2 receptor antagonistsAlkylating agents +[5]

TargetsHistamine H2 receptorCyclooxygenasesLeukotriene +[4]

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesIsrael

CombinationsYes Cyclophosphamide Diclofenac Sodium Cimetidine

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTiltan Pharma

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTiltan Pharma Ltd

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms, Castration-ResistantPancreatic Neoplasms

Other Information

ATC CodeN/A